Stockscreener 앱 받기
33.61
2.47%
0.81
시간 외 거래:
34.00
0.39
+1.16%
전일 마감가:
$32.80
열려 있는:
$32.68
하루 거래량:
1.17M
Relative Volume:
0.77
시가총액:
$1.74B
수익:
$190.41M
순이익/손실:
$20.48M
주가수익비율:
150.85
EPS:
0.2228
순현금흐름:
$46.66M
1주 성능:
-8.52%
1개월 성능:
-14.72%
6개월 성능:
-38.60%
1년 성능:
-31.10%
1일 변동 폭
$32.34
$33.72
1주일 범위
$32.15
$36.65
52주 변동 폭
$32.15
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
33.61 | 1.69B | 190.41M | 20.48M | 46.66M | 0.2228 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-10-07 | 개시 | Goldman | Buy |
| 2025-08-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-23 | 개시 | TD Cowen | Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman - marketscreener.com
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman - GlobeNewswire Inc.
Soleno Lawsuit Puts DCCR Safety Disclosures And Growth Story Under Scrutiny - simplywall.st
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Soleno - GlobeNewswire
DEADLINE ALERT for BSX, EOSE, SLNO, and NKTR: The Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Soleno ... - Bluefield Daily Telegraph
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT - GlobeNewswire
Soleno Therapeutics Faces Class Action Lawsuit - National Today
Soleno Therapeutics stock hits 52-week low at 32.51 USD By Investing.com - Investing.com South Africa
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - GlobeNewswire Inc.
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hy - GuruFocus
Oppenheimer Lowers Soleno Therapeutics (NASDAQ:SLNO) Price Target to $80.00 - MarketBeat
Soleno Therapeutics Seen Beating 2026 Sales Estimates Despite Slower Vykat XR US Launch, Oppenheimer Says - marketscreener.com
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman – Company AnnouncementFT.com - Financial Times
Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week LowHere's What Happened - MarketBeat
Soleno Therapeutics stock hits 52-week low at 32.51 USD - Investing.com
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky - PR Newswire
Oppenheimer Adjusts Price Target on Soleno Therapeutics to $80 From $110, Maintains Outperform Rating - marketscreener.com
Oppenheimer cuts Soleno Therapeutics stock price target on slower launch By Investing.com - Investing.com South Africa
Oppenheimer cuts Soleno Therapeutics stock price target on slower launch - Investing.com
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Soleno Therapeutics : February 2026 Corporate Presentation - marketscreener.com
Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating - MSN
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Soleno Therapeutics, Inc. (SLNO) Class Action Lawsuit Seeks Recovery for Investors; May 5, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - The Globe and Mail
SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Cla - GuruFocus
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Holocene Advisors LP Trims Stake in Soleno Therapeutics, Inc. $SLNO - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages Soleno Therapeutics, - GlobeNewswire
Soleno Therapeutics, Inc. (SLNO) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Chronicle-Journal
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 – Company Announcement - Financial Times
Soleno Therapeutics, Inc. 8-K Filing Details, Company Information, and Amended Bylaws (March 16, 2026) - Minichart
Soleno Therapeutics Target of Unusually Large Options Trading (NASDAQ:SLNO) - MarketBeat
Granahan Investment Management Boosts Stake in Soleno Therapeutics - National Today
Soleno Therapeutics amends bylaws to update governance and legal provisions - Investing.com
Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class ActionRGRD Law - PR Newswire
Soleno Therapeutics (SLNO) Board adopts amended and restated bylaws - Stock Titan
Soleno Therapeutics Inc (NASDAQ:SLNO) Emerges as a Potential Fair-Value Opportunity - ChartMill
301,000 Shares in Soleno Therapeutics, Inc. $SLNO Purchased by Kingdon Capital Management L.L.C. - MarketBeat
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):